JP2014503591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503591A5 JP2014503591A5 JP2013551334A JP2013551334A JP2014503591A5 JP 2014503591 A5 JP2014503591 A5 JP 2014503591A5 JP 2013551334 A JP2013551334 A JP 2013551334A JP 2013551334 A JP2013551334 A JP 2013551334A JP 2014503591 A5 JP2014503591 A5 JP 2014503591A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- alkoxy
- cycloalkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 125000003545 alkoxy group Chemical group 0.000 claims 42
- 125000001424 substituent group Chemical group 0.000 claims 30
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000003302 alkenyloxy group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000005133 alkynyloxy group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- -1 stereoisomers Chemical class 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- YXEMEJDLTDSPMD-UHFFFAOYSA-N n-[1-(2h-tetrazol-5-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=CC=C2CCCCC2=C1C1=NN=NN1 YXEMEJDLTDSPMD-UHFFFAOYSA-N 0.000 claims 1
- DRXLVIJGMCULCP-UHFFFAOYSA-N n-[3-bromo-2-(2h-tetrazol-5-yl)phenyl]benzenesulfonamide Chemical compound N=1N=NNC=1C=1C(Br)=CC=CC=1NS(=O)(=O)C1=CC=CC=C1 DRXLVIJGMCULCP-UHFFFAOYSA-N 0.000 claims 1
- JMQWCCHJBYWWOP-UHFFFAOYSA-N n-[3-methoxy-2-(2h-tetrazol-5-yl)phenyl]benzenesulfonamide Chemical compound N=1N=NNC=1C=1C(OC)=CC=CC=1NS(=O)(=O)C1=CC=CC=C1 JMQWCCHJBYWWOP-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161436265P | 2011-01-26 | 2011-01-26 | |
| US61/436,265 | 2011-01-26 | ||
| PCT/US2012/022721 WO2012103333A1 (en) | 2011-01-26 | 2012-01-26 | Tetrazole compounds and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503591A JP2014503591A (ja) | 2014-02-13 |
| JP2014503591A5 true JP2014503591A5 (enExample) | 2015-03-12 |
| JP6058557B2 JP6058557B2 (ja) | 2017-01-11 |
Family
ID=45688985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551334A Expired - Fee Related JP6058557B2 (ja) | 2011-01-26 | 2012-01-26 | テトラゾール化合物ならびにその作製方法および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9321740B2 (enExample) |
| EP (1) | EP2668169B1 (enExample) |
| JP (1) | JP6058557B2 (enExample) |
| KR (1) | KR20140006888A (enExample) |
| CN (1) | CN103402989B (enExample) |
| BR (1) | BR112013018771A2 (enExample) |
| CA (1) | CA2825408A1 (enExample) |
| MX (1) | MX344238B (enExample) |
| WO (1) | WO2012103333A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2011044506A2 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| WO2011085201A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Fumagillol type compounds and methods of making and using same |
| US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| CA2814413A1 (en) | 2010-10-12 | 2012-04-19 | Zafgen, Inc. | Sulphonamide compounds and methods of making and using same |
| JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン，インコーポレイテッド | ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
| BR112013018771A2 (pt) | 2011-01-26 | 2019-09-17 | Zafgen Inc | compostos de tetrazol e métodos para fazer e usar os mesmos |
| BR112013023056A2 (pt) | 2011-03-08 | 2018-10-09 | Zafgen Inc | derivados de oxaespiro [2,5] octano e análogos |
| EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| AU2012253757B2 (en) | 2011-05-06 | 2017-04-13 | Zafgen Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| WO2012154679A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
| EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
| MX2014008705A (es) | 2012-01-18 | 2015-02-05 | Zafgen Inc | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. |
| KR20140112565A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| MX2014013599A (es) | 2012-05-08 | 2015-05-11 | Zafgen Inc | Tratamiento de la obesidad hipotalamica con inhibidores de metap2. |
| KR20150016534A (ko) | 2012-05-09 | 2015-02-12 | 자프겐 인크. | 푸마지롤형 화합물 및 이의 제조 및 사용 방법 |
| BR112015010223A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos para o uso no tratamento e/ou controle de obesidade |
| JP2015536981A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン，インコーポレイテッド | 三環式化合物ならびにその製造および使用方法 |
| BR112015010196A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
| MX362391B (es) | 2013-03-14 | 2019-01-15 | Zafgen Inc | Métodos de tratamiento de enfermedad renal y otros trastornos. |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| CN106749068A (zh) * | 2017-01-18 | 2017-05-31 | 昆山力田医化科技有限公司 | 阿佐塞米中间体合成方法 |
| JP2019052115A (ja) * | 2017-09-15 | 2019-04-04 | 国立研究開発法人理化学研究所 | 医薬組成物 |
| WO2019135920A1 (en) * | 2018-01-03 | 2019-07-11 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors and methods of use thereof |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| DE68927904T2 (de) | 1988-09-01 | 1997-09-04 | Takeda Chemical Industries Ltd | Fumagillol-Derivate |
| EP0387650B1 (en) | 1989-03-06 | 1993-03-31 | Takeda Chemical Industries, Ltd. | 6-epifumagillols, production and use thereof |
| US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
| US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| TW282399B (enExample) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| ATE205092T1 (de) | 1992-01-30 | 2001-09-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe |
| ATE153854T1 (de) | 1992-12-16 | 1997-06-15 | Takeda Chemical Industries Ltd | Stabile pharmazeutische zubereitung mit fumagillolderivaten |
| JP3260378B2 (ja) | 1995-03-27 | 2002-02-25 | サノフィーサンテラボ | 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用 |
| CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
| EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| AU3968597A (en) | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
| KR20000075954A (ko) | 1997-03-04 | 2000-12-26 | 죤 에이치. 뷰센 | Ｎ-히드록시 4-술포닐 부탄아미드 화합물 |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| WO1998056372A1 (en) | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| WO1999039702A2 (en) | 1997-10-31 | 1999-08-12 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| KR20010033470A (ko) | 1997-12-23 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 염증성 질병과 아테롬성경화증의 치료 또는 예방을 위한티오우레아 및 벤즈아미드 화합물, 조성물 및 방법 |
| ES2317688T3 (es) * | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| EE200100558A (et) | 1999-04-28 | 2002-12-16 | Aventis Pharma Deutschland Gmbh | Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine |
| WO2001024796A1 (en) | 1999-10-01 | 2001-04-12 | Smithkline Beecham Corporation | 1,2,4-triazole derivatives, composition, process of making and methods of use |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| AR030631A1 (es) | 2000-09-29 | 2003-08-27 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
| CN1505617A (zh) | 2000-11-01 | 2004-06-16 | ������˹ҩƷ��˾ | 作为Met-AP2抑制剂的肽 |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| ES2329553T4 (es) | 2000-12-20 | 2010-12-07 | Bristol-Myers Squibb Company | Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. |
| US20040116495A1 (en) | 2001-03-29 | 2004-06-17 | Marino Jr. Joseph P. | Compounds and methods |
| US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
| WO2003027104A1 (en) | 2001-09-27 | 2003-04-03 | Idrtech Inc. | Fumagillol derivatives and preparing method thereof |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040068012A1 (en) | 2002-10-08 | 2004-04-08 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| CA2534887A1 (en) | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| US7396833B2 (en) | 2003-12-22 | 2008-07-08 | Memory Pharmaceuticals Corporation | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| CA2550873A1 (en) | 2003-12-29 | 2005-07-21 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
| KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
| WO2005113513A2 (en) * | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
| AU2005259864A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| MX2007003623A (es) | 2004-09-24 | 2007-09-11 | Johnson & Johnson | Compuestos sulfonamida. |
| CN101142210A (zh) | 2005-01-26 | 2008-03-12 | 株式会社钟根堂 | 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物 |
| FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| US20070078172A1 (en) | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| SI1962830T1 (sl) | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
| US20100234364A1 (en) * | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
| EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| JP5557746B2 (ja) | 2007-11-28 | 2014-07-23 | メルサナ セラピューティックス，インク． | 生体適合性生分解性フマギリンアナログ複合体 |
| ATE506359T1 (de) | 2007-11-30 | 2011-05-15 | Bayer Schering Pharma Ag | Heteroaryl-substituierte piperidine |
| NZ590732A (en) | 2008-07-18 | 2012-09-28 | Zafgen Inc | Methods of treating an overweight or obese subject using fumagillin |
| EP2350012B1 (en) | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| CA2741683C (en) | 2008-10-24 | 2016-03-22 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2010065879A2 (en) * | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2011044506A2 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
| US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
| US20130210821A1 (en) | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| CA2814413A1 (en) | 2010-10-12 | 2012-04-19 | Zafgen, Inc. | Sulphonamide compounds and methods of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
| WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
| JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン，インコーポレイテッド | ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
| US20140011870A1 (en) | 2010-11-29 | 2014-01-09 | Zafgen, Inc. | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
| BR112013018771A2 (pt) | 2011-01-26 | 2019-09-17 | Zafgen Inc | compostos de tetrazol e métodos para fazer e usar os mesmos |
| AU2012253757B2 (en) | 2011-05-06 | 2017-04-13 | Zafgen Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| WO2012154679A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
| EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
-
2012
- 2012-01-26 BR BR112013018771A patent/BR112013018771A2/pt not_active IP Right Cessation
- 2012-01-26 KR KR1020137021714A patent/KR20140006888A/ko not_active Withdrawn
- 2012-01-26 MX MX2013008656A patent/MX344238B/es active IP Right Grant
- 2012-01-26 WO PCT/US2012/022721 patent/WO2012103333A1/en not_active Ceased
- 2012-01-26 US US13/981,502 patent/US9321740B2/en not_active Expired - Fee Related
- 2012-01-26 JP JP2013551334A patent/JP6058557B2/ja not_active Expired - Fee Related
- 2012-01-26 CA CA2825408A patent/CA2825408A1/en not_active Abandoned
- 2012-01-26 EP EP12704958.3A patent/EP2668169B1/en active Active
- 2012-01-26 CN CN201280010890.3A patent/CN103402989B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503591A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| JP2015518004A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| RU2014131058A (ru) | Средство, усиливающее действие противоопухолевых средств | |
| JP2014526492A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2014525420A5 (enExample) | ||
| JP2013527243A5 (enExample) | ||
| JP2015503609A5 (enExample) | ||
| JP2013531031A5 (enExample) | ||
| JP2014505660A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2016512520A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2014513138A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2015516427A5 (enExample) |